Citation Report
List of articles citing

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

DOI: 10.1056/nejmoa1701830
New England Journal of Medicine, 2017, 377, 1836-1846.

Source: https://exaly.com/paper-pdf/67450283/citation-report.pdf
Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
854	Neoadjuvant chemotherapy for early breast cancer - Author's reply. **2018**, 19, e130		
853	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. **2018**, 19, 474-485		39
852	A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine. **2018**, 36, 517-522		4
851	Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register. **2018**, 57, 935-940		12
850	Breast-Cancer Recurrence after Stopping Endocrine Therapy. *New England Journal of Medicine*, **2018**, 378, 870-871	59.2	5
849	[The 20-year results of 5-year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. **2018**, 59, 410-412		1
848	Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction. **2018**, 105, 1435-1445		7
847	Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?. **2018**, 29, 1096-1098		4
846	Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. **2018**, 170, 455-476		25
845	How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?. **2018**, 168, 773-774		9
844	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. **2018**, 168, 639-647		15
843	Clinical Update. **2018**, 20, 7-7		
842	20-year risk of breast cancer recurrence. **2018**, 168, 765-766		7
841	Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. **2018**, 41, 59-65		60
840	Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. **2018**, 144, 1253-1263		25
839	Brustkrebs: h□fig Sp□rezidive nach antihormoneller Therapie. **2018**, 23, 15-15		
838	Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. **2018**, 19, 26		32

837	Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. **2018**, 20, 48		2
836	A parallel model for breast cancer metastasis. **2018**, 170, 443-444		
835	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. **2018**, 25, R83-R113		11
834	Disseminated breast tumour cells: biological and clinical meaning. **2018**, 15, 129-131		24
833	Brustkrebs: Häufig Spätrezidive nach antihormoneller Therapie. **2018**, 21, 15-16		
832	Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond. **2018**, 38, 38-46		7
831	New and Important Changes in the TNM Staging System for Breast Cancer. **2018**, 38, 457-467		37
830	[Survival of patients with advanced HER2+ breast cancer. Analysis of a cancer center database]. **2018**, 146, 1095-1101		1
829	Caring of Breast Cancer Patient. **2018**,		
828	Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. **2018**, 1100, 83-95		8
827	Understanding the Bone in Cancer Metastasis. **2018**, 33, 2099-2113		145
826	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 1946-1953	59.2	2
825	An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. **2018**, 8, 634		17
824	FoxP1 "Tspans" Quiescence and Activation of Mammary Stem Cells. **2018**, 47, 539-540		
823	Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers. **2018**, 159, 3897-3907		34
822	S3-Leitlinie: Endokrine Therapie des primären Mammakarzinoms. **2018**, 51, 548-555		2
821	Enrichment and detection of bone disseminated tumor cells in models of low tumor burden. **2018**, 8, 14299		12
820	Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?. **2018**, 23, 1153-1161		18

819	The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. **2018**, 10,	4
818	Screening women with a personal history of breast cancer: overview of the evidence on breast imaging surveillance. **2018**, 37, 277-287	17
817	Dormant tumour cells, their niches and the influence of immunity. **2018**, 20, 1240-1249	83
816	Clinical outcomes comparison of 10´years versus 5´years of adjuvant endocrine therapy in patients with early breast cancer. **2018**, 18, 977	8
815	Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. **2018**, 35, 831-846	17
814	Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity against Lung Cancer. **2018**, 30, e1805437	6
813	Profile of abemaciclib and its potential in the treatment of breast cancer. **2018**, 11, 5253-5259	17
812	Major clinical research advances in gynecologic cancer in 2017. **2018**, 29, e31	18
811	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. **2018**, 20, 103	7
810	SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. **2018**, 11, 208-212	2
809	The Pan-Cytokeratin Staining Intensity and Fractal Computational Analysis of Breast Tumor Malignant Growth Patterns Prognosticate the Occurrence of Distant Metastasis. **2018**, 8, 348	7
808	Targeting Peroxisome Proliferator-Activated Receptor to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells. **2018**, 17, 2732-2745	18
807	Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. **2018**, 98, 687-702	16
806	Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. **2018**, 171, 359-369	28
805	Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients. **2018**, 95, 147-155	11
804	A rude awakening from tumour cells. **2018**, 554, 35-36	7
803	CDK4/6 inhibition in breast cancer: current practice and future directions. **2018**, 10, 1758835918786451	167
802	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. **2018**, 4, 1700-1706	101

801	Precision Medicine in Hormone Receptor-Positive Breast Cancer. **2018**, 8, 144		22
800	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. **2018**, 20, 72		39
799	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. **2018**, 10, 1758835918777437		6
798	TAILORing Adjuvant Systemic Therapy for Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 191-192	59.2	4
797	Indications for Post-Mastectomy Radiation Therapy After Neoadjuvant Chemotherapy. **2018**, 18, e767-e768		
796	Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. **2018**, 119, 313-322		3
795	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health. **2018**, 159, 2980-2990		13
794	Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. **2018**, 94, 812-822		12
793	Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients. **2018**, 171, 33-41		3
792	Überraschend hohes Risiko für Spätrezidive. **2018**, 21, 42-42		
791	Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. **2018**, 102, 82-94		11
790	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. **2018**, 70, 118-126		9
789	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 122-137	59.2	270
788	Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. **2018**, 29, 1777-1783		41
787	Heterogeneity in Outcomes of Pathologic T1-2N1 Breast Cancer After Mastectomy: Looking Beyond Locoregional Failure Rates. **2018**, 25, 2288-2295		16
786	Sensitivity and Isoform Specificity of F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer. **2018**,		13
785	Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. **2019**, 5, 1304-1309		15
784	Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer. **2019**, 38, 6913-6925		14

783	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. **2019**, 30, 1541-1557	288
782	Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer-Bad Blood. **2019**, 5, 1479-1480	5
781	Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer. **2019**, 97, 180-188	1
780	Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism. **2019**, 7, e871	8
779	Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study. **2019**, 19, 659	12
778	Schwangerschaft nach einer Tumorerkrankung. **2019**, 17, 65-70	0
777	Adjuvant Endocrine Therapy. **2019**, 135-152	
776	HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer. **2019**, 12, 473-479	2
775	Management Strategies for Locally Recurrent Breast Cancer: Redo-Lumpectomy, Redo-Sentinel Node Biopsy, Redo-Radiation. **2019**, 26, 3018-3024	3
774	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. **2019**, 47, 77-84	9
773	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. **2019**, 37, 3425-3435	27
772	Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?. **2019**, 30, 1677-1681	
771	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. **2019**, 22, 387-398	1
770	. **2019**,	3596
769	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. **2019**, 3, pkz050	6
768	Individual participant data. **2019**, 643-658	15
767	Cost-utility analysis of 21-gene assay for node-positive early breast cancer. **2019**, 26, 307-318	4
766	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. **2019**, 11,	24

765	At the Boundaries of Homeownership: Credit, Discrimination, and the American State. **2019**, 106, 514-515	
764	Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. **2019**, 30, 1776-1783	49
763	Metastatic Latency, a Veiled Threat. **2019**, 10, 1836	8
762	CDK4/6 inhibitors in advanced breast cancer, what is beyond?. **2019**, 13, 416	3
761	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. **2019**, 9, 12184	17
760	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. **2019**, 3, pkz062	2
759	Breast Cancer Dormancy in Bone. **2019**, 17, 353-361	13
758	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. **2019**, 10, 3840	52
757	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. **2019**, 5, 26	8
756	The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. **2019**, 2047487319874900	20
755	Breast cancer. **2019**, 5, 66	698
754	Breast Cancer Treatment: A Review. **2019**, 321, 288-300	1202
753	Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. **2019**, 21, 238-250	118
752	Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer. **2019**, 26, 1214-1224	17
751	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. **2019**, 74, 29-34	11
750	Bone as a Preferential Site for Metastasis. **2019**, 3, e10126	22
749	Factors influencing the use of extended adjuvant endocrine therapy. **2019**, 175, 181-189	4
748	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. **2019**, 7, 27	31

747	Breast cancer follow-up after a primary diagnosis: A confused picture. **2019**, 46, 97-100		1
746	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. **2019**, 20, 1136-1147		57
745	Prognosis and cure´of long-term cancer survivors: A population-based estimation. **2019**, 8, 4497-4507		13
744	The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche. **2019**, 17, 100244		31
743	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. **2019**, 118, 178-186		23
742	Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. **2019**, 25, 5388-5397		17
741	The Precision of Evidence Needed to Practice "Precision Medicine". *New England Journal of Medicine*, **2019**, 380, 2472-2474	59.2	10
740	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up **2019**, 30, 1194-1220		528
739	Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. **2019**, 10, 245		75
738	Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data. **2019**, 61, 185-189		3
737	Management of Breast Cancer in Older Women. **2019**,		
736	Focus on Formononetin: Anticancer Potential and Molecular Targets. **2019**, 11,		63
735	Prediction of Distant Recurrence Using EndoPredict Among Women with ER, HER2 Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. **2019**, 25, 3865-3872		36
734	Predicting late recurrence in ER-positive breast cancer. **2019**, 16, 406-408		2
733	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ER breast cancer. **2019**, 10, 2115		27
732	(-)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models. **2019**, 11,		20
731	Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?. **2019**, 104, 869-876		6
730	Defining the Hallmarks of Metastasis. **2019**, 79, 3011-3027		194

729	Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance. **2019**, 11,	8
728	Dual TGF/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. **2019**, 17, 1556-1570	11
727	Tumor dormancy at bedside: A late awakening. **2019**, 45, 61-63	6
726	Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. **2019**, 175, 733-740	13
725	Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. **2019**, 8, 1755-1764	15
724	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. **2019**, 20,	8
723	The Unfolded Protein Response in Cancer. **2019**,	1
722	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. **2019**, 42, 352-362	22
721	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. **2019**, 567, 399-404	108
720	Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients. **2019**, 14, e0212527	0
719	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. **2019**, 25, 3996-4013	41
718	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. **2019**, 37, 105-114	38
717	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. **2019**, 37, 636-646	52
716	Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer. **2019** , 12, 2071-2078	1
715	Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. **2019**, 30, 1044-1050	16
714	Implication of environmental estrogens on breast cancer treatment and progression. **2019**, 421, 41-48	13
713	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. **2019**, 37, 1365-1369	9
712	Liquid biopsy and minimal residual disease - latest advances and implications for cure. **2019**, 16, 409-424	379

711	"It is not just any pill"-Women's experiences of endocrine therapy after breast cancer surgery. **2019**, 28, e13009	3
710	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. **2019**, 21, 25	71
709	Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo. **2019**, 70, 110-116	39
708	Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Co-expressing Tumors. **2019**, 119-133	
707	Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. **2019**, 110, 53-61	7
706	Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015. **2019**, 44, 153-159	13
705	Genetic Ancestry-dependent Differences in Breast Cancer-induced Field Defects in the Tumor-adjacent Normal Breast. **2019**, 25, 2848-2859	11
704	Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients. **2019**, 14, 159-164	0
703	Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. **2019**, 175, 287-295	10
702	Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management. **2019**, 171, 925-930	7
701	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis. **2019**, 24, e1014-e1023	1
700	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. **2019**, 21, 123	14
699	Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy. **2019**, 5, 41	14
698	Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor. **2019**, 9, 16942	31
697	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. **2019**, 21, 153	7
696	Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. **2019**, 48 Suppl 1, S89-S91	2
695	Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. **2019**, 48 Suppl 1, S85-S88	0
694	Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications. **2019**, 11,	19

693	Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin. **2019**, 11,	13
692	Diagnosis and Treatment of Breast Cancer in Young Women. **2019**, 20, 86	25
691	3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. **2019**, 14, 211	8
690	Letter in reply. **2019**, 8, 1261-1263	
689	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. **2019**, 31, 43-51	5
688	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. **2019**, 48 Suppl 1, S81-S84	1
687	High risk for cardiovascular disease in postmenopausal breast cancer survivors. **2019**, 26, 1024-1030	7
686	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. **2019**, 1-26	
685	Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features. **2019**, 31, 29-34	8
684	Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study. **2019**, 42, 588-595	12
683	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers.. **2019**, 3, 1-13	
682	Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer. **2019**, 3, 1-12	21
681	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. **2019**, 24, 165-171	13
680	Progress in adjuvant systemic therapy for breast cancer. **2019**, 16, 27-44	96
679	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. **2019**, 16, 296-311	33
678	OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. **2019**, 26, 815-820	3
677	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. **2019**, 151-188	1
676	The link between wound healing and escape from tumor dormancy. **2019**, 28, 50-56	4

675	Estrogen Receptor and Breast Cancer. **2019**,	3
674	Crosstalk between Estrogen Signaling and Breast Cancer Metabolism. **2019**, 30, 25-38	46
673	Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study. **2019**, 44, 52-58	12
672	Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. **2019**, 236, 288-299	5
671	Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. **2019**, 21, 2	20
670	Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. **2019**, 144, 263-272	56
669	Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?. **2019**, 125, 177-180	3
668	Hormonal Treatment of Breast Cancer. **2019**, 646-655	1
667	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. **2019**, 111, 339-341	7
666	Predictors of time to death after distant recurrence in breast cancer patients. **2019**, 173, 465-474	12
665	Subtypes in BRCA-mutated breast cancer. **2019**, 84, 192-201	13
664	Cancer Policy: Pharmaceutical Safety. **2019**,	
663	Cancer Drug Toxicity: Moving from Patient to Survivor. **2019**, 171, 107-118	1
662	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. **2019**, 20, 88-99	58
661	Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery. **2019**, 134, 10-21	9
660	The Impact of Breast Density Reporting Laws on Women's Awareness of Density-Associated Risks and Conversations Regarding Supplemental Screening With Providers. **2019**, 16, 139-146	29
659	[Excess mortality among breast cancer patients in early stages in Tarragona and Gerona (Spain)]. **2020**, 34, 356-362	
658	Specialist breast cancer nurses' views on implementing a fear of cancer recurrence intervention in practice: a mixed methods study. **2020**, 28, 201-210	6

657	Correcting a decade of negative news about mammography. **2020**, 60, 265-270	4
656	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. **2020**, 6, 116-124	289
655	Multigene assays in early breast cancer: Insights from recent phase 3 studies. **2020**, 46, 656-666	11
654	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. **2020**, 38, 1293-1303	45
653	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. **2020**, 38, 1258-1267	19
652	Long-term prognostic effect of hormone receptor subtype on breast cancer. **2020**, 179, 139-151	2
651	Cell-intrinsic survival signals. The role of autophagy in metastatic dissemination and tumor cell dormancy. **2020**, 60, 28-40	10
650	Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5´years after diagnosis and late recurrence. **2020**, 27, 54-61	13
649	Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer. **2020**, 77, 559-572	9
648	CinBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. **2020**, 49, 17-24	2
647	Fertility Challenges and Solutions in Women with Cancer. **2020**,	
646	Internal mammary node irradiation improves 8-year survival in breast cancer patients: results from a retrospective cohort study in real-world setting. **2020**, 27, 252-260	3
645	Hormone Effects on Tumors. **2020**, 667-693	1
644	A prognostic eight-gene expression signature for patients with breast cancer receiving adjuvant chemotherapy. **2019**, 121, 3923	6
643	Evidence-based follow-up for breast cancer. **2020**, 13, 60-63	0
642	17Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study. **2020**, 59, 329-333	2
641	Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate. **2020**, 26, 25-34	12
640	Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. **2020**, 26, 623-631	6

639	IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. **2020**, 146, 2348-2359	6
638	Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). **2020**, 19, 47-53	10
637	Breast cancer prevention in high-risk women. **2020**, 65, 18-31	44
636	Window of opportunity treatment in breast cancer. **2020**, 90, 34-40	1
635	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR/HER2 Metastatic Breast Cancer. **2020**, 20, e232-e243	13
634	When Should Oncologists Use the Words and ?. **2020**, 4, pkaa066	
633	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. **2020**, 26, 6523-6534	4
632	Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. **2020**, 12,	3
631	Clinical practice to address tamoxifen nonadherence. **2020**, 184, 675-682	
630	Developing themes in targeted therapies for hormone receptor‐positive breast cancer. **2020**, 15, 15-23	
629	Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. **2020**, 9, 7810-7818	3
628	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. **2020**, 22, 123	1
627	Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis. **2020**, 156, 103114	5
626	Cancer progression and the invisible phase of metastatic colonization. **2020**, 20, 681-694	60
625	Management of hormone receptor-positive, HER2-negative early breast cancer. **2020**, 47, 187-200	8
624	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. **2020**, 31, 1359-1365	3
623	Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow. **2020**, 39, 5649-5662	12
622	Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors. **2020**, 27, 127-134	1

621	Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. **2020**, 183, 251-262	1
620	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. **2020**, 54, 235-241	6
619	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. **2020**, 10, 594514	5
618	Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer. **2021**, 217, 587-594	2
617	Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy. **2020**, 12, 123-130	
616	Accelerated Partial Breast Radiation: Information on Dose, Volume, Fractionation, and Efficacy from Randomized Trials. **2020**, 108, 1123-1128	2
615	Omitting radiotherapy is safe in breast cancer patients ≥70 years old after breast-conserving surgery without axillary lymph node operation. **2020**, 10, 19481	5
614	Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. **2020**, 10, 13078	8
613	Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients. **2020**, 12, 771-781	1
612	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. **2020**, 38, 3273-3281	10
611	Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH Breast Cancer Stem Cells. **2020**, 15, 307-316	16
610	Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer-Impact on Prognosis. **2020**, 10, 1278	0
609	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. **2020**, 10, 1315	3
608	Endocrine Therapy in Early Breast Cancer. **2020**, 15, 337-346	13
607	Validation of an Algorithm to Ascertain Late Breast Cancer Recurrence Using Danish Medical Registries. **2020**, 12, 1083-1093	3
606	Prognostic factors in patients with oligometastatic breast cancer - A systematic review. **2020**, 91, 102114	9
605	Hormonal Regulation of Semaphorin 7a in ER Breast Cancer Drives Therapeutic Resistance. **2021**, 81, 187-198	8
604	Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer. **2020**, 161,	4

603	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. **2020**, 10, 1335	1
602	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. **2020**, 184, 783-795	1
601	A Hierarchical Structured Ultrafine Fiber Device for Preventing Postoperative Recurrence and Metastasis of Breast Cancer. **2020**, 30, 2004851	13
600	Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. **2020**, 12,	1
599	DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development. **2020**, 6, 37	6
598	Adjuvante endokrine Therapie beim primären Mammakarzinom. **2020**, 14, 27-42	
597	Letter by Kizawa et al Regarding Article, "Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study". **2020**, 142, e154-e155	1
596	The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. **2020**, 40, 484-500	33
595	Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. **2020** , 12,	6
594	Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells. **2020**, 80, 4828-4839	3
593	Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. **2020**, 12,	11
592	Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. **2020**, 63, 14530-14559	25
591	Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort. **2020**, 6, 1363-1369	0
590	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. **2020**, 5, e000743	4
589	Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer. **2020**, 21, 84	1
588	Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. **2020**, 6, 35	14
587	Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. **2020**, 21,	21
586	Wntless (Wls): A Prognostic Index for Progression and Patient Survival of Breast Cancer. **2020**, 13, 12649-12659	1

585	Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer. **2020**, 22, 139		5
584	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. *New England Journal of Medicine*, **2020**, 383, 2557-2570	59.2	38
583	Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. **2020**, 12,		1
582	Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment. **2020**, 15, 43-48		1
581	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. **2020**, 12, 381-390		
580	Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools. **2020**, 25, 237-253		4
579	MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer. **2020**, 21,		30
578	Implementing preoperative endocrine therapy in breast cancer. **2020**, 21, 1390-1392		
577	Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. **2020**, 52, 701-708		89
576	Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers. **2020**, 14, 2271-2287		10
575	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. **2020**, 9, 4603-4612		2
574	Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer. **2020**, 39, 4896-4908		17
573	Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer. **2020**, 43, 334-339		
572	The dormant cancer cell life cycle. **2020**, 20, 398-411		107
571	Breast cancer: are long-term and intermittent endocrine therapies equally effective?. **2020**, 146, 2041-2049		3
570	Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer. **2020**, 52, 64-70		4
569	Switching Homes: How Cancer Moves to Bone. **2020**, 21,		5
568	Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer. **2020**, 12,		10

567	Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. **2020**, 85, 1141-1152		7
566	Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis. **2020**, 76, 1199-1211		2
565	Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. **2020**, 10, 199-223		28
564	Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. **2020**, 16, e517-e528		1
563	Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation. **2020**, 9, 3234-3243		19
562	Models of Breast Cancer Metastatic Dormancy. **2020**, 8, 37		14
561	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. **2020**, 8,		28
560	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. **2020**, 122, 1611-1617		4
559	The Role of Nicotinamide in Cancer Chemoprevention and Therapy. **2020**, 10,		31
558	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. **2020**, 26, 171-182		4
557	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. **2020**, 26, 2556-2564		32
556	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. **2020**, 395, 817-827		116
555	Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery. **2020**, 32, 390-396		7
554	Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. **2020**, 10, 4091		4
553	Understanding ER+ Breast Cancer Dormancy Using Bioinspired Synthetic Matrices for Long-Term 3D Culture and Insights into Late Recurrence. **2020**, 4, e2000119		10
552	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. *New England Journal of Medicine*, **2020**, 383, 262-272	59.2	12
551	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. **2020**, 2020, 3759179		10
550	The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. **2020**, 27, 3393-3401		3

549	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer. **2020**, 77, 900-914	3
548	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. **2020**, 14, 1179554920931816	2
547	Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution. **2020**, 33, 2499-2506	8
546	Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. **2020**, 367, 1468-1473	88
545	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. **2020**, 579, 284-290	109
544	A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells. **2020**, 147, 519-531	3
543	Automated volumetric radiomic analysis of breast cancer vascularization improves survival prediction in primary breast cancer. **2020**, 10, 3664	5
542	Trends in Late Mortality Among Adolescent and Young Adult Cancer Survivors. **2020**, 112, 994-1002	17
541	Roles of Splicing Factors in Hormone-Related Cancer Progression. **2020**, 21,	6
540	Vascular co-option. **2020**, 33-47	1
539	Rationally Designed Ruthenium Complexes for Breast Cancer Therapy. **2020**, 25,	30
538	Cytokeratin 5 alters β-catenin dynamics in breast cancer cells. **2020**, 39, 2478-2492	12
537	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial. **2020**, 6, 528-534	11
536	Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines. **2020**, 11, 76-86	4
535	Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review. **2020**, 22, 13	18
534	The Canary in the Coal Mine: Biomaterial Implants to Monitor Cancer Recurrence. **2020**, 80, 377-378	
533	Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature. **2020**, 22, 15	12
532	ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). **2020**, 31, 674-696	80

531	Overcoming Endocrine Resistance in Breast Cancer. **2020**, 37, 496-513	121
530	A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. **2020**, 112, 979-988	5
529	A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. **2020**, 26, 1888-1889	0
528	Single-Cell Probe Force Studies to Identify Sox2 Overexpression-Promoted Cell Adhesion in MCF7 Breast Cancer Cells. **2020**, 9,	5
527	Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. **2020**, 181, 369-381	12
526	Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer. **2020**, 20, e481-e489	2
525	Correlation between the contrast-enhanced ultrasound image features and axillary lymph node metastasis of primary breast cancer and its diagnostic value. **2021**, 23, 155-163	2
524	The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. **2021**, 28, 67-74	2
523	The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16[F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review. **2021**, 92, 24-37	19
522	Prognostic and predictive parameters in breast pathology: a pathologist's primer. **2021**, 34, 94-106	3
521	Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?. **2021**, 21, e53-e62	4
520	. **2021**, 5, pkaa084	1
519	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. **2021**, 21, 80-91.e7	52
518	Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy. **2021**, 36, 131-142	1
517	Updates on the treatment of invasive breast cancer: Quo Vadimus?. **2021**, 145, 64-72	3
516	Intra-tumoural lipid composition and lymphovascular invasion in breast cancer via non-invasive magnetic resonance spectroscopy. **2021**, 31, 3703-3711	6
515	Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. **2021**, 500, 64-74	2
514	Relationship between lymphovascular invasion and molecular subtypes in invasive breast cancer. **2021**, 75, e13897	2

513	FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. **2021**, 27, 1842-1849	33
512	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. **2021**, 186, 115-123	6
511	Stem cell niches in bone and their roles in cancer metastasis. **2021**, 5, 35-62	
510	An evaluation of palbociclib as a breast cancer treatment option: a current update. **2021**, 22, 281-290	2
509	Immunotherapy for early breast cancer: too soon, too superficial, or just right?. **2021**, 32, 323-336	28
508	Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development. **2021**, 73, 58-75	4
507	On the Road to Precision: Understanding the Biology Driving Genomic Assays. **2021**, 39, 100-102	2
506	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. **2021**, 127, 700-708	0
505	Nachsorge nach Mammakarzinomerkrankung. **2021**, 54, 77-82	1
504	A Case of Pulmonary Metastasis of Breast Cancer 23 Years after Surgery Accompanied with Non-Tuberculous Mycobacterium Infection. **2020**, 13, 1357-1363	
503	Molecular Drivers of Onco DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. **2021**, 39, 126-135	20
502	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR Early-stage Breast Cancer for 10 Years of Endocrine Therapy. **2021**, 27, 311-319	17
501	The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen. **2021**, 498, 54-69	9
500	Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. **2021**, 11, 2259	2
499	Genistein Reduces the Risk of Local Mammary Cancer Recurrence and Ameliorates Alterations in the Gut Microbiota in the Offspring of Obese Dams. **2021**, 13,	7
498	Liquid biopsy enters the clinic - implementation issues and future challenges. **2021**, 18, 297-312	158
497	Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ER+ breast cancer cells.	1
496	Female-specific cancer. **2021**, 179-192	

495	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. **2021**, 27, 41-49	5
494	Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. **2021**, 4, 762-783	2
493	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. **2021**, 27, 1855-1863	17
492	Role of myeloid-derived suppressor cells in metastasis. **2021**, 40, 391-411	6
491	IQGAP3 Overexpression Correlates With Poor Prognosis and Radiation Therapy Resistance in Breast Cancer. **2020**, 11, 584450	6
490	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. **2021**, 12,	4
489	Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. **2021**, 19, 1026-1039	0
488	Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. **2021**, 187, 843-852	2
487	Clinical management and biology of tumor dormancy in breast cancer. **2021**,	5
486	CD39PD-1CD8 T cells mediate metastatic dormancy in breast cancer. **2021**, 12, 769	10
485	Analgesic efficacy and safety of erector spinae plane block in breast cancer surgery: a systematic review and meta-analysis. **2021**, 21, 59	4
484	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. **2021**, 13,	1
483	The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer. **2021**, 112, 1369-1375	1
482	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. **2021**, 23, 21	4
481	CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer. **2021**, 55, 75-78	5
480	Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer. **2021**, 187, 135-144	1
479	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. **2021**, 22, 212-222	64
478	Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. **2021**, 11, 5566	1

477	A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results. **2021**, 11, 576007	3
476	Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer. **2021**, 13, e14088	
475	The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study. **2021**, 11, 653243	1
474	Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. **2021**, 22, 341-350	14
473	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. **2021**, 7,	1
472	Cáncer de mama. **2021**, 13, 1506-1517	
471	Bone marrow niches in the regulation of bone metastasis. **2021**, 124, 1912-1920	13
470	Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer. **2021**, 39, 307-309	2
469	Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. **2021**, 187, 455-465	0
468	Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial. **2021**, 156, 596-606	1
467	Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer. **2021**, 26, e943-e953	6
466	Factors associated with late risks of breast cancer-specific mortality in the SEER registry. **2021**, 189, 203-212	1
465	The development and initial validation of the Breast Cancer Recurrence instrument (BreastCaRe)-a patient-reported outcome measure for detecting symptoms of recurrence after breast cancer. **2021**, 30, 2671-2682	1
464	Late Recurrence in Breast Cancer: To Run after the Oxen or to Try to Close the Barn?. **2021**, 13,	
463	Breast cancer larger than 2.5´cm with tumor-free radioisotope-hot sentinel nodes has higher risk of non-hot axillary lymph node metastasis.. **2021**,	0
462	PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN. **2021**, 20, 16-23	1
461	Metastasis-Initiating Cells and Ecosystems. **2021**, 11, 971-994	22
460	Evaluation of circulating tumor cells as a prognostic biomarker for early recurrence in stage II-III breast cancer patients using CytoSorter system: a retrospective study. **2021**, 9, e11366	2

459	Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial. **2021**, 113, 1352-1359	3
458	The role of functional polymorphisms in oxidative stress-related genes on early-stage breast cancer survival. **2021**, 36, 14-21	0
457	Unperturbed dormancy recording reveals stochastic awakening strategies in endocrine treated breast cancer cells.	1
456	Endokrine Kombinationstherapien beim lokal fortgeschrittenen, metastasierten Mammakarzinom zusammen besser als allein. **2021**, 54, 309-319	
455	Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer. **2021**, 113, 1274-1276	1
454	Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer. **2021**, 78, 100939	2
453	Novel approaches to target the microenvironment of bone metastasis. **2021**, 18, 488-505	16
452	Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?. **2021**, 127, 3302-3309	1
451	Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. **2021**, 23, 54	9
450	The many faces of cancer evolution. **2021**, 24, 102403	4
449	Causal Attributions in Breast Cancer Patients Planning to Undergo Adjuvant Endocrine Therapy. **2021**, 18,	1
448	Estrogen Modulates Epithelial Breast Cancer Cell Mechanics and Cell-to-Cell Contacts. **2021**, 14,	2
447	Oncologic Safety of Autologous Fat Grafting after Breast Cancer Surgical Treatment: A Matched Cohort Study. **2021**, 148, 11-20	3
446	The risk of contralateral breast cancer: a SEER-based analysis. **2021**, 125, 601-610	4
445	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. **2021**, 7, 66	8
444	Breast cancer. **2021**, 397, 1750-1769	126
443	Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor. **2021**, 13,	3
442	Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy. **2021**, 41,	6

441	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. **2021**,	1
440	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. **2021**, 13,	2
439	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. **2021**, 149, 117-127	4
438	Myeloid derived suppressor cells and the release of micro-metastases from dormancy. **2021**, 38, 279-293	4
437	Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. **2021**, 21, 487	0
436	Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer. **2021**, 39, 1506-1507	
435	Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. **2021**, 32, 642-651	8
434	Evaluation of the ability of the Clinical Treatment Score at 5´years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients. **2021**, 28, 1131-1140	2
433	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. **2021**, 41, 1-15	1
432	Gastric Metastasis of Breast Cancer Found on Routine Esophageal Variceal Screening. **2021**, 14, 162	
431	Using data mining technology to predict medication-taking behaviour in women with breast cancer: A retrospective study. **2021**,	
430	Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer. **2021**, 13, 141	6
429	Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination. **2021**, 17, 1975-1992	3
428	Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.	
427	Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?. **2021**, 189, 463-470	0
426	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. **2021**, 59, 1-8	2
425	Selection of Adjuvant Endocrine Therapy for Women With Breast Cancer in Menopausal Transition: Is It Simpler Than We Thought?. **2021**, 113, 1444-1446	1
424	Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort. **2021**, 6, 100151	3

423	The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings. **2021**,		4
422	The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer. **2021**, 11,		0
421	Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. **2021**, 4, e2114904		3
420	Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. **2021**, 57, 5-17		6
419	Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women's Decision Making in an Online Breast Cancer Forum. **2021**, 9,		0
418	Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. **2021**, 11, 691277		1
417	TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication. **2021**, 10,		3
416	The rate of estrogen receptor-conversion associated with tumor progression in estrogen receptor-positive breast cancer patients following adjuvant Tamoxifen administration. **2021**, e1431		2
415	Breast cancer in young women: Imaging and clinical course. **2021**, 27, 657-663		1
414	Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness. **2021**, 13,		0
413	Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. **2021**, 189, 797-806		1
412	Multiphoton microscopy for monitoring the occurrence, metastasis and therapy of breast cancer. **2021**, 63, 2470-2491		
411	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. *New England Journal of Medicine*, **2021**, 385, 395-405	59.2	8
410	Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. **2021**, 7, 90		
409	From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. **2021**, 13,		3
408	Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. **2021**, 12, 713700		5
407	Collective metastasis: coordinating the multicellular voyage. **2021**, 38, 373-399		7
406	Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer. **2021**, 43, 1228-1244.e4		4

405	Extended Aromatase Inhibitors in Hormone-Receptor-Positive Breast Cancer. *New England Journal of Medicine*, **2021**, 385, 462-463	59.2	0
404	Epithelial-mesenchymal plasticity determines estrogen receptor positive (ER+) breast cancer dormancy and reacquisition of an epithelial state drives awakening.		0
403	Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. **2021**, 13,		0
402	Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. **2021**, 531, 111321		3
401	Hormonoterapia adyuvante en cáncer de mama. Revisión de la Evidencia y Abordaje Terapéutico en el Instituto Instituto Nacional de Cancerología, Bogotá Colombia. 25, 130-141		
400	Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer. **2021**,		0
399	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. **2021**, 21, 1037-1048		2
398	F-fluorodeoxyglucose (FDG) PET or F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. **2021**, 23, 88		1
397	Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. **2021**, 67, 1240-1248		0
396	Heterogeneity of estrogen receptor based on 18F-FES PET imaging in breast cancer patients. 1		0
395	Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk. **2021**, 13,		1
394	Hormonoterapia en cáncer de mama metastásico. Revisión de la Evidencia y Abordaje Terapéutico en el Instituto Nacional de Cancerología, Bogotá Colombia. 25, 142-151		
393	Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer. **2021**,		0
392	Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy. **2021**, 13,		1
391	Bioelectrical impedance vector applied to body composition evaluation of women survivors of breast cancer: A longitudinal study. **2021**, 44, 247-253		1
390	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. **2021**, 99, 713-721		
389	Human Papillomavirus in Breast Carcinogenesis: A Passenger, a Cofactor, or a Causal Agent?. **2021**, 10,		3
388	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. **2021**, 22, 1139-1150		24

387	Prognostic Significance of -GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer. **2021**, 11,	0
386	Extended adjuvant aromatase inhibitor therapy: less is more.. **2021**, 2, 996-998	
385	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. **2021**, 190, 451-462	0
384	Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives. **2021**, 13,	0
383	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. **2021**, 9,	2
382	Prognostic and tumor-immune infiltration cell signatures in tamoxifen-resistant breast cancers. **2021**, 10, 2766-2779	0
381	Single-cell profiling defines the prognostic benefit of CD39 tissue resident memory CD8+ T cells in luminal-like breast cancer. **2021**, 4, 1117	2
380	Plant-Based Dietary Patterns and Breast Cancer Recurrence and Survival in the Pathways Study. **2021**, 13,	0
379	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. **2021**, 39, 2893-2902	3
378	Breast Cancer Classification Prediction Based on Ultrasonic Image Feature Recognition. **2021**, 2021, 4025597	0
377	Reply to T. Suemasu et al. **2021**, 39, 2966-2968	
376	Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study. **2021**, 110, 1613-1621	0
375	Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer. **2021**, 50, 128335	1
374	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. **2021**, 22, 1458-1467	7
373	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. **2021**, 32, 1216-1235	44
372	Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. **2021**, 59, 367-375	1
371	Transcriptional Profiling of Tumorspheres Reveals TRPM4 as a Novel Stemness Regulator in Breast Cancer. **2021**, 9,	4
370	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. **2021**, 100, 102264	4

369	Magnetic resonance imaging radiomics signatures for predicting endocrine resistance in hormone receptor-positive non-metastatic breast cancer. **2021**, 60, 90-97	2
368	Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-positive Breast Cancer. **2021**, 35, 761-777	1
367	Next-Generation Clinical Trials and Research with Successful Collaborations. **2021**, 1187, 613-622	
366	Capecitabine as Maintenance Therapy for High-Risk, Resected Colorectal Cancer. **2021**, 8, 81-86	
365	Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review. **2021**, 27, 100358	
364	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ-Reply. **2020**, 6, 1118	2
363	Endocrine Therapy in Clinical Practice. **2019**, 215-240	1
362	Targeted degradation of activating estrogen receptor ligand-binding domain mutations in human breast cancer. **2020**, 180, 611-622	22
361	Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients. **2021**, 15, 621-628	1
360	Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges. **2020**, 486, 29-37	11
359	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. **2018**, 191, 65-73	41
358	Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. **2021**, 20, 65-80	4
357	Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. **2020**, 133, 548-558	10
356	IQGAP3 Overexpression Correlates with Poor Prognosis and Radiation Therapy Resistance in Breast Cancer.	1
355	SREBP1 drives KRT80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ER breast cancer.	1
354	Single-cell Transcriptomics reveals multi-step adaptations to endocrine therapy.	1
353	Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance.	2
352	A dormant sub-population expressing interleukin-1 receptor characterises anti-estrogen resistant ALDH+ breast cancer stem cells.	2

351	Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases.	2
350	Stromal integrin β1 regulates PDGFR-β signaling and promotes breast cancer progression. **2019**, 129, 4609-4628	52
349	Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. **2020**, 130, 4252-4265	34
348	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. **2020**, 130, 4871-4887	15
347	Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. **2020**, 22, 140	7
346	ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. **2020**, 22, 16	25
345	Do we still need breast cancer screening in the era of targeted therapies and precision medicine?. **2020**, 11, 105	16
344	Comparison of diagnostic sensitivity of [F]fluoroestradiol and [F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. **2020**, 10, 54	10
343	Connection between SOX7 Expression and Breast Cancer Prognosis. **2020**, 26, e921510	1
342	G-Protein-Coupled Receptor 5 (LGR5) Overexpression Activates β-Catenin Signaling in Breast Cancer Cells via Protein Kinase A. **2019**, 25, 15-25	5
341	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. **2020**, 12, e11908	35
340	Maternal obesity increases offspring's mammary cancer recurrence and impairs tumor immune response. **2020**, 27, 469-482	5
339	90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. **2020**, 65, T35-T48	8
338	90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future. **2020**, 65, T49-T63	13
337	[Role of biological heterogeneity in recurrent and metastatic breast cancer]. **2018**, 80, 62-67	5
336	Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. **2018**, 5, 40-50	5
335	New insights into acquired endocrine resistance of breast cancer. **2019**, 2, 198-209	19
334	Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. **2019**, 13, 24-28	1

333	Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/β-catenin signaling pathway. **2020**, 22, 4868-4876	7
332	Updates in endocrine therapy for metastatic breast cancer. **2021**,	0
331	Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control. **2021**,	0
330	Time-Restricted Eating: A Novel and Simple Dietary Intervention for Primary and Secondary Prevention of Breast Cancer and Cardiovascular Disease. **2021**, 13,	0
329	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. **2021**, OP2100482	1
328	Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction. **2021**, 19, 307	2
327	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. **2021**, 99, 1691-1710	2
326	Redox Control of the Dormant Cancer Cell Life Cycle. **2021**, 10,	1
325	Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?. **2021**, 13,	2
324	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. **2021**, 23, 95	1
323	Racial and Ethnic Disparities in Rates of Invasive Secondary Breast Cancer Among Women With Ductal Carcinoma In Situ in Hawai'i. **2021**, 4, e2130925	
322	Nut consumption in association with overall mortality and recurrence/disease-specific mortality among long-term breast cancer survivors. **2021**,	2
321	Risk of cancer lingers after breast-tumour diagnosis. **2017**, 551, 275-275	
320	Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.	
319	Adjuvant Endocrine Therapy for Breast Cancer. **2019**, 413-432	
318	Adjuvant Systemic Therapy: Endocrine Therapy. **2019**, 103-127	
317	The Unfolded Protein Response as an Integrator of Response to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer. **2019**, 163-180	
316	Correlation of radiotherapy with prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping. **2019**, 31, 471-480	1

315	Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients. **2019**, 56, 293-296	
314	Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model. **2019**, 26, 339-353	1
313	Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?. **2019**, 11, e5417	1
312	ZMIZ1 A novel Estrogen Receptor co-activator that enhances the growth of ER+ breast cancer.	
311	Impact of Systemic Anticancer Therapy on Fertility. **2020**, 67-80	
310	Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. **2019**, 18, 6690-6696	3
309	Brain Metastases Cell Partners and Tumor Microenvironment. **2020**, 59-71	0
308	CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer.	
307	PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer. **2020**, 40,	4
306	Possible applications of salvianolic acid B against different cancers. **2020**, 1, 218-238	0
305	Systemic Staging (Total Body When, How). **2022**, 297-305	
304	Conditioned media from MCF7 and BT474 breast cancer cells induce insulin resistance in skeletal muscle myotubes.	1
303	Biological prospectives of hybrid nanostructures. **2020**, 33-55	
302	Personalized Management of Cancers of Various Organs/Systems. **2021**, 509-602	
301	Optimizing Decision Making for Ductal Carcinoma in Situ: Facts Over Fear. **2021**, 113, 511-512	
300	Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive lobular carcinoma of the breast.	0
299	Breast cancer: Emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.	
298	Prostate cancer dormancy and recurrence. **2022**, 524, 103-108	4

297	Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer. **2020**, 16, 17-22	1
296	The Mammary Tumor Microenvironment. **2020**, 1296, 163-181	
295	Sexualhormone. **2020**, 621-648	
294	Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer.	
293	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. **2021**, 1	0
292	Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study. **2021**, 23, 103	2
291	Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ER breast cancer cells. **2021**, 118,	0
290	The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. **2021**,	9
289	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ER-positive breast cancer. **2020**, 1, 355-371	2
288	Metastasis: A Bane of Breast Cancer Therapy.	
287	Case report: 16-yr life history and genomic evolution of an ER HER2 breast cancer. **2020**, 6,	0
286	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. **2020**, 20, 1-234	7
285	Mammakarzinom. **2022**, 340-351	
284	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. **2021**, 1	5
283	Chromosome breaks in breast cancers occur near herpes tumor virus sequences and explain why cancer drugs stop working.	
282	Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. **2021**, OP2100720	
281	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. **2021**, 11, 772530	2
280	Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present). **2021**,	3

279	Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients. **2021**,	2
278	microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study.. **2022**, 73, 103092	3
277	Antimetastatic defense by CD8 T cells. **2021**,	2
276	Copy number heterogeneity identifies ER+ breast cancer patients with adverse outcome after adjuvant endocrine therapy.	
275	Organ-on-a-chip model of vascularized human bone marrow niches. **2021**, 121245	4
274	Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study. **2021**, 1	1
273	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. **2021**, 5,	2
272	Development of novel agents for the treatment of early estrogen receptor positive breast cancer.. **2021**,	
271	Alcohol Consumption: Discussing Potential Risks for Informed Decisions in Breast Cancer Survivors. **2021**, 25, 672-679	
270	Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. **2021**,	1
269	Adjuvant abemaciclib for high-risk breast cancer: the story continues. **2021**, 32, 1457-1459	0
268	The Usefulness of Ultrasound Surveillance for Axillary Recurrence in Women With Personal History of Breast Cancer. 24,	
267	Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.. **2022**, 11, 134-147	1
266	Risk for relapse and death after adjuvant chemotherapy associated with SNPs in patients with breast cancer - A retrospective study.. **2022**, 30, 100505	
265	Improving the Therapeutic Ratio Among Older Women With Early Stage Breast Cancer by Reevaluating Adjuvant Radiation Therapy and Hormone Therapy.. **2022**, 112, 52-55	0
264	Modulating gene expression in breast cancer via DNA secondary structure and the CRISPR toolbox.. **2021**, 3, zcab048	1
263	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.. **2021**, 13,	0
262	Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.. **2022**,	1

261	Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.. **2022**, 22, 102	2
260	Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. **2022**, 14,	1
259	Effects of Propofol Sevoflurane on Postoperative Breast Cancer Prognosis: A Narrative Review.. **2021**, 11, 793093	1
258	The Usefulness of Ultrasound Surveillance for Axillary Recurrence in Women With Personal History of Breast Cancer.. **2021**,	0
257	The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.. **2022**, 40, 989	0
256	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. **2022**, JCO2102019	4
255	Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression. **2021**, 15, 101302	0
254	How we treat HR-positive, HER2-negative early breast cancer.. **2022**,	0
253	Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer.. **2022**, 14,	1
252	Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells.. **2022**, 22, 18	
251	Metastatic Breast Cancer Recurrence after Bone Fractures.. **2022**, 14,	1
250	CKAP2L, transcriptionally inhibited by FOXP3, promotes breast carcinogenesis through the AKT/mTOR pathway.. **2022**, 412, 113035	0
249	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.. **2022**, 236, 108108	4
248	The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting. **2022**, 2022, 1-7	0
247	Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer.. **2022**,	1
246	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. **2022**, 1	0
245	Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study.. **2022**,	1
244	Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.. **2022**,	6

243	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.. **2022**,	7
242	The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery.. **2022**,	
241	SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. **2022**,	
240	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.. **2021**, 11, 667397	1
239	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. **2021**,	2
238	All-in-one superparamagnetic and SERS-active niosomes for dual-targeted in vitro detection of breast cancer cells.	1
237	Prognostic Significance of Lobular Carcinoma In-Situ (LCIS) Diagnosed Alongside Invasive Breast Cancer.. **2022**, 16, 11782234211070217	
236	Molecular sensors for detection of tumor-stroma crosstalk.. **2022**, 154, 47-91	1
235	Mortality After Late Breast Cancer Recurrence in Denmark.. **2022**, JCO2102062	1
234	Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy.. **2022**,	0
233	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.. **2022**,	2
232	Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review.. **2022**, 14,	1
231	Breast cancer. **2022**, 1196-1207	
230	Genetic and epigenetic driven variation in regulatory regions activity contribute to adaptation and evolution under endocrine treatment.	0
229	Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer.. **2022**, 1	
228	Tumor Dormancy: Biologic and Therapeutic Implications.. **2022**, 13, 8-19	2
227	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. **2022**, 6, e2100181	2
226	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.. **2022**, 164, 52-61	

225	Ribociclib efficacy in special populations and analysis of patient reported outcomes in the MONALEESA trials.. **2022**,	2
224	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.. **2022**, 12, 813462	0
223	Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer.. **2022**,	
222	Estrogen and Estrogen Receptor Modulators: Potential Therapeutic Strategies for COVID-19 and Breast Cancer.. **2022**, 13, 829879	0
221	Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.. **2022**,	1
220	The nebula of chronicity: dealing with metastatic breast cancer in the UK.. **2022**, 1-15	
219	Late Recurrence Following Early Breast Cancer.. **2022**, JCO2200167	0
218	miR-126 Decreases Proliferation and Mammosphere Formation of MCF-7 and Predicts Prognosis of ER+ Breast Cancer.. **2022**, 12,	1
217	The Impact Oncoplastic Reduction Has on Long-Term Recurrence in Breast Conservation Therapy.. **2022**,	1
216	The Impact of Statin Use and Breast Cancer Recurrence -´A Retrospective Study in Singapore.. **2022**, 12, 835320	0
215	Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.. **2022**, 13, 838040	0
214	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer.. **2022**,	
213	Locoregional tumor burden and risk of mortality in metastatic breast cancer.. **2022**, 6, 22	1
212	mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.. **2021**,	1
211	Bioactive cationic peptides as potential agents for breast cancer treatment. **2021**, 41,	
210	Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis. **2021**,	2
209	Metastatic Invasive Lobular Carcinoma of the Breast Presenting Peritoneal Metastasis with Bilateral Ureteral Obstruction.. **2021**, 43, 409-414	
208	Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment.. **2021**, 26, 399	0

207	Current status of AYA-generation breast cancer: trends worldwide and in Japan.. **2021**, 27, 16	
206	TRIM39 is a poor prognostic factor for patients with estrogen receptor-positive breast cancer and promotes cell cycle progression.. **2022**, 72, 96-106	0
205	Expression is a Potential Prognostic Biomarker for Postoperative Metastasis in Lymph Node-Negative Early-Stage Invasive Breast Carcinoma Patients.. **2021**, 14, 1701-1713	
204	Risk factors of local relapses in patients with breast cancer depending on the properties of the primary tumor. **2021**, 43, 67-73	
203	Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence.. **2022**, 29, 10732748221089412	1
202	Factores perioperatorios en el cancer de mama. Revisi sistemtica de su influencia en el pronstico. **2022**,	
201	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.. **2022**, 14,	1
200	LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.. **2022**, 8, 49	0
199	A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time.. **2022**, 12, 6352	
198	The ELEANOR non-coding RNA expression contributes to cancer dormancy and predicts late recurrence of ER-positive breast cancer.. **2022**,	1
197	Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer.. **2022**,	0
196	Table_1.pdf. **2020**,	
195	Table_2.pdf. **2020**,	
194	DataSheet_1.pdf. **2020**,	
193	Data_Sheet_1.docx. **2020**,	
192	Image_1.TIF. **2020**,	
191	Image_2.TIF. **2020**,	
190	Image_1.TIF. **2020**,	

189	Table_1.DOCX. **2020**,	
188	Image_1.TIF. **2018**,	
187	Table_1.DOCX. **2018**,	
186	Table_2.DOCX. **2018**,	
185	Biodegradable electrospun nanofibrous platform integrating antiplatelet therapy-chemotherapy for preventing postoperative tumor recurrence and metastasis.. **2022**, 12, 3503-3517	0
184	ELEVATED CA 15.3 IN NEWLY DIAGNOSED BREAST CANCER: A RETROSPECTIVE STUDY. **2022**,	0
183	Phenotypic plasticity during metastatic colonization.. **2022**,	1
182	The Genetic Evolution of Metastasis.. **2022**, OF1-OF9	0
181	Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research. **2022**, 24, 115-118	
180	ACR Appropriateness Criteria Imaging of the Axilla.. **2022**, 19, S87-S113	
179	Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR.. **2022**, 8, 58	1
178	Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies. **2022**,	0
177	Epigenetics Involvement in Breast Cancer. **2022**, 145-183	
176	Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy.. **2022**, 12, 866293	0
175	Treatment of Breast Cancer in Young Adults.. **2022**, 42, 1-12	2
174	Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis.. **2022**, 1	0
173	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.. **2022**,	
172	The Applications of Plasma Cell-free DNA in Cancer Detection: Implications in the Management of Breast Cancer Patients. **2022**, 103725	

171	A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.	1
170	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. **2022**, 1-13	0
169	The History of Early Breast Cancer Treatment. **2022**, 13, 960	0
168	Therapeutische Behandlung der minimalen Resterkrankung zur Verhinderung von Spätrezidiven bei Hormonrezeptor-positivem Brustkrebs: Herausforderungen und neue Ansätze. 1-11	
167	High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. **2022**, 17, e0268799	
166	The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation. **2022**, 23,	
165	Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia. **2022**, 17,	
164	CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation. **2022**, 219,	0
163	Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?.	0
162	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.	1
161	Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors. **2022**, 14, 2848	
160	Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.	
159	Tumor cell conditioned media drives collagen remodeling via fibroblast and pericyte activation in an in vitro premetastatic niche model. **2022**, 104645	1
158	Use of Diagnostic Imaging Modalities in Modern Screening, Diagnostics and Management of Breast Tumours 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. 28,	0
157	Analysis of the Role of Continuous Early Intervention in Improving the Quality of Life of Breast Cancer Patients. **2022**, 2022, 1-10	0
156	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Publish Ahead of Print,	
155	Recent insights into the effects of metabolism on breast cancer cell dormancy.	0
154	Exogenous Hormones and Breast Cancer Risk: Contraception, Menopausal Hormone Therapy, and Breast Cancer Survivors. Publish Ahead of Print,	

153	Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.	1
152	PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2. **2022**, 12,	0
151	Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. **2022**, 1877, 188749	2
150	Extended endocrine therapy in breast cancer: A basket of length-constraint feature selection metaheuristics to balance Type I against Type II errors. **2022**, 131, 104112	
149	Preventing late recurrence in hormone receptor-positive early breast cancer: a review. **2022**, 172, 53-64	
148	The Role of the Microenvironment in Tumor Promoting Stress Responses. **2022**, 519-536	
147	Targeted Intraoperative Radiotherapy (TARGIT-IORT) for Early-Stage Invasive Breast Cancer: A Single Institution Experience. 12,	0
146	Prognosticating 2-Year Survival Rate of Breast Cancer Patients Through Plasma miRNA-21 and Other Associating Factors. Volume 15, 5557-5566	
145	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.	
144	Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer: A Literature Review. **2022**, 29, 4956-4969	0
143	Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer: impact on patient anxiety and cancer detection. **2022**, 22,	0
142	Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer. **2022**, 194, 507-516	
141	CACA Guidelines for Holistic Integrative Management of Breast Cancer. **2022**, 1,	
140	Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ESTIMATE tool. **2022**, 173, 20-29	0
139	Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.	1
138	Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.	
137	Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged 70 years with ultralow risk of distant recurrence: A population-based cohort study.. **2022**,	0
136	Bone-Targeted Agents and Metastasis Prevention. **2022**, 14, 3640	1

135	Evaluation of metabolic syndrome and obesity in breast cancer survivors undergoing interdisciplinary approach: a prospective cohort study. 32,	
134	Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer. Publish Ahead of Print,	
133	Identifying Breast Cancer Recurrence in Administrative Data: Algorithm Development and Validation. **2022**, 29, 5338-5367	0
132	Firmas g□icas en el c□cer de mama. **2022**, 35, S67-S86	
131	The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.	1
130	Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. **2022**, 13,	1
129	The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective study.	
128	Marker assessments in ER positive breast cancers - old markers, new applications?.	0
127	Extracellular vesicles in bone homeostasis: key roles of physiological and pathological conditions.	0
126	Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer. **2022**, 2022, 1-13	
125	The Palpable Nodule After Autologous Fat Grafting: Distinguishing Benign Versus Malignant Lesions in a Breast Reconstruction Cohort. Publish Ahead of Print,	0
124	Cholesterol Synthesis Is Important for Breast Cancer Cell Tumor Sphere Formation and Invasion. **2022**, 10, 1908	1
123	Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin. **2022**, 17, e0273513	
122	ESO-ESMO 5th International Consensus Guidelines for Breast Cancer in Young Women (BCY5). **2022**,	0
121	The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. **2022**,	
120	In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor□Positive Breast Cancer.	
119	Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients.	0
118	Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis.	1

117	Nonparametric kernel estimation of the probability of cure in a mixture cure model when the cure status is partially observed. 096228022211158	0
116	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer.	1
115	Prediction of lymph node metastasis in patients with breast invasive micropapillary carcinoma based on machine learning and SHapley Additive exPlanations framework. 12,	1
114	Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. **2022**, 175, 169-179	0
113	Follow-up Guidelines, Evidence, and Recommendations. **2022**, 221-224	0
112	Factors Associated with Plasma Levels of Tamoxifen and its Main Metabolites in Mexican Patients with Breast Cancer. **2022**, 19,	0
111	Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis. **2022**, 14, 4197	0
110	Long term risk of distant metastasis in women with non-metastatic breast cancer and survival after metastasis detection: a population-based linked health records study.	0
109	New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24 non-hematopoietic rare cell phenotype with breast cancer residual disease.	0
108	PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. **2022**, 22,	0
107	Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer. **2022**, 23, 10539	0
106	Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. **2022**, 8,	0
105	Molecular characterization of ESR1 variants in breast cancer.	0
104	Local recurrence of mammary Paget s disease after nipple-sparing mastectomy and implant breast reconstruction: a case report and literature review. **2022**, 20,	0
103	Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer.	1
102	Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.	0
101	Gastric metastasis of breast cancer: A frequent mimicker of primary gastric cancer in breast cancer patients.	0
100	Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a´retrospective study. **2022**, 176, 58-69	0

99	Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients. **2022**, 155, 113787	0
98	A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer. **2022**, 21, 153303382211326	0
97	Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors. **2022**, 303-330	0
96	Recidiva locorregional del cáncer de mama. **2022**, 58, 1-20	0
95	Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.	0
94	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. 12,	0
93	Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2‐Negative Postmenopausal Breast Cancer Patients. **2022**, 14, 4844	0
92	Comment on ‘The lingering mysteries of metastatic recurrence in breast cancer’	0
91	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. **2022**, 14, 5206	1
90	Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction. **2022**, 196, 657-664	0
89	Adherence to Mediterranean Diet and Nutritional Status in Women with Breast Cancer: What Is Their Impact on Disease Progression and Recurrence-Free Patients’ Survival?. **2022**, 29, 7482-7497	0
88	Cancer Stem Cells. 1-12	0
87	Follow-up and Cancer Survivorship. **2022**,	0
86	Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer. **2022**, 22,	1
85	Neoplasms of the Breast. 1-62	0
84	Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s).	2
83	Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review. **2022**,	0
82	Complex RNA world in small extracellular vesicles for liquid biopsy in cancer management. **2022**, 1, 100015	1

81	Receptor-ligand non-equilibrium kinetics (RLNEK) 1.0: An integrated Trackmate laminar flow chamber analysis. **2022**, 511, 113381	0
80	Cancer du sein et greffe d'organes : revue systématique et méta-analyse. **2022**,	0
79	Challenges and Changes of the Breast Cancer Screening Paradigm.	0
78	Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis. **2023**, 181, 103880	0
77	Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer. **2023**, 37, 89-102	0
76	Standards of adherence to cancer prevention guidelines in female breast cancer survivors. **2022**, 24, 1-7	0
75	Generation and Evaluation of Hydrogel-Facilitated 3D Tumor Microenvironments of Breast Cancer. **2022**, 12,	0
74	The initial experience of MRI-guided precision prone breast irradiation with daily adaptive planning in treating early stage breast cancer patients. 12,	0
73	Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience. **2022**,	0
72	Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer. **2022**, 12,	0
71	Concomitant administration of warfarin and toremifene: A case report. **2022**, 47, 2383-2386	0
70	A diverse treatment with the extract of Euphorbia fischeriana Steud. and Ziziphus jujuba Mill. for breast cancer nude mice of MCF-7 (ER+) cells or MDA-MB-453 (ER-) cells via modulation of the PI3k/Akt signalling pathway. **2022**, 5, 100198	0
69	Are the common genetic 3'UTR variants in ADME genes playing a role in tolerance of breast cancer chemotherapy?.	0
68	Cited1 as a Marker of Favourable Outcome in Anti-endocrine Treated Er-positive, Lymph Node Negative Breast Cancer.	0
67	Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.	0
66	Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer.	0
65	Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.	0
64	Dynamic Biobanking for Advancing Breast Cancer Research.	0

63	Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.	0
62	Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. **2022**, 24,	0
61	Identification of a novel ER-NFB-driven stem-like cell population associated with relapse of ER+ breast tumors. **2022**, 24,	0
60	Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. **2022**,	1
59	Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature. **2022**, 16,	0
58	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.	1
57	Breast Cancer. **2022**, 133-181	0
56	Do circulating neutrophil extracellular traps predict recurrence in early breast cancer?. 12,	0
55	Mining TCGA Database for Genes with Prognostic Value in Breast Cancer. **2023**, 24, 1622	0
54	Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptorpositive breast cancer. 12,	0
53	PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. **2023**, 25,	0
52	Sirolimus-exuding core-shell nanofibers as an implantable carrier for breast cancer therapy: preparation, characterization, in vitro cell studies, and in vivo anti-tumor activity. 1-14	0
51	Role of myeloid-derived suppressor cells in tumor recurrence.	1
50	ESR1 Mutations as a Predictor of Progression and Metastasis of Hormone-Dependent Breast Cancer. **2022**, 7, 6-15	0
49	SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. **2022**, 24,	0
48	Matrix metalloproteinases as therapeutic targets in breast cancer. 12,	0
47	Modulating Glycolysis to Improve Cancer Therapy. **2023**, 24, 2606	0
46	MRI-LINAC: A transformative technology in radiation oncology. 13,	0

45	Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. **2023**, 13,	1
44	Circulating Tumour Cells in Solid Cancer. **2023**, 115-147	0
43	Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis. **2023**, 86, 207-219	0
42	Editorial: Revisiting seed and soil: A new approach to target hibernating dormant tumor cells. 13,	0
41	Cáncer y embarazo. **2023**, 59, 1-11	0
40	Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. **2023**, 129, 1173-1182	0
39	Dynamic Biobanking for Advancing Breast Cancer Research. **2023**, 13, 360	0
38	Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. 14,	0
37	Computational modeling of locoregional recurrence with spatial structure identifies tissue-specific carcinogenic profiles. 13,	0
36	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. Volume 15, 251-261	0
35	Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer. **2023**, 23,	0
34	Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ER degraders and HDAC inhibitors. **2023**, 134, 106459	0
33	Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer. **2023**, 245, 154428	0
32	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. **2023**, 69, 258-264	0
31	Involvement of redox signalling in tumour cell dormancy and metastasis. **2023**, 42, 49-85	0
30	Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration?. **2023**, 49, 1079-1082	0
29	Analyzing breast cancer invasive disease event classification through explainable artificial intelligence. 10,	2
28	B3GALT6 Promotes Dormant Breast Cancer Cell Survival and Recurrence by Enabling Heparan Sulfate-Mediated FGF Signaling.	0

27	Tamoxifen evolution. **2023**, 128, 421-425	0
26	Metal-coordination synthesis of a natural injectable photoactive hydrogel with antibacterial and blood-aggregating functions for cancer thermotherapy and mild-heating wound repair. **2023**, 11, 2486-2503	0
25	A Local Strategy Toward Concurrent Chemoradiotherapy Based on Fibrin Gel for Postsurgical Cancer Treatment. **2023**,	0
24	ER Sensitizes and ER Desensitizes ER-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid. **2023**, 24, 3747	0
23	Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients Needs?. Volume 15, 147-161	0
22	How I treat endocrine-dependent metastatic breast cancer. **2023**, 8, 100882	0
21	Ten-Year Oncologic Outcomes in T1-3N1 Breast Cancer After Targeted Axillary Sampling: A Retrospective Study.	0
20	Advances in Breast Cancer Screening: Precision, Imaging, and Harms. **2023**, 1-27	0
19	A Review of Endocrine Therapy in Early-stage Breast Cancer. Publish Ahead of Print,	0
18	Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. **2023**, 211-232	0
17	Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence. **2023**, 31,	0
16	Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians. **2023**, 24, 4974	0
15	Nondisparate Survival of Non-Hispanic Black Women With Breast Cancer Despite Less Favorable Pathology: Effect of Access to and Provision of Care Within a Military Health Care System. **2023**, 7, 178-184	0
14	Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse.	0
13	Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.	0
12	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. **2023**, 58, 101901	0
11	A Multiomic Analysis Reveals How Breast Cancers Disseminated to the Bone Marrow Acquire Aggressive Phenotypes through Tumor-Stroma Tunnels.	0
10	Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date. Volume 16, 189-196	0

9	Analysis of the breast cancer progression frequency depending on the amount of surgical treatment performed after neoadjuvant drug therapy. **2023**, 10, 50-56	0
8	Clinical factors affecting the long-term survival of breast cancer patients. **2023**, 51, 030006052311640	0
7	The Future of Breast Cancer Research in the Survivorship Field.	0
6	CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.	0
5	Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. **2023**, 9,	0
4	Metastasis. **2023**, 186, 1564-1579	0
3	Identifying recurrent breast cancer patients in national health registries using machine learning. 1-8	0
2	Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.	0
1	Multi-omics analysis reveals a molecular landscape of the early recurrence and early metastasis in pan-cancer. 14,	0